SCHEMBL22450707

SCHEMBL22450707

CC(=O)c1nn(C)c2ccc(F)cc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SSTR4 P31391 2/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44
▸ NAMPT P43490 3/20 0.41
▸ ELANE P08246 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ SCN9A Q15858 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ HTR3A P46098 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ HCRTR1 O43613 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ICMT O60725 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20646913 0.87 L3MBTL1 (0.44) L3MBTL1SSTR4KDM4CKDM4EALDH1A1
SCHEMBL15025470 0.87 KDM4C (0.49) SSTR4KDM4CNAMPTELANEKDM4E
SCHEMBL16252830 0.86 SCN9A (0.51) SSTR4KDM4CNAMPTELANEKDM4E
SCHEMBL20592780 0.85 METAP2 (0.42) L3MBTL1SSTR4KDM4CNAMPTKDM4E
SCHEMBL22450682 0.81 GABRA1 (0.51) KDM4CNAMPTELANEKDM4E
SCHEMBL29989752 0.81 KDM4E (0.39) L3MBTL1KDM4CKDM4EALDH1A1HSD17B10
SCHEMBL17324761 0.79 ICMT (0.39) L3MBTL1ELANEKDM4EALDH1A1HPGD
SCHEMBL20593161 0.78 BRD4 (0.35) L3MBTL1SSTR4KDM4CNAMPTGRIN1
SCHEMBL18967147 0.77 ICMT (0.40) L3MBTL1KDM4CELANEKDM4EALDH1A1
SCHEMBL18591437 0.77 CFD (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220175917-A1 COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-06-09 — — US disclosed
EP-3936126-A1 COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-01-12 — — EP disclosed
EP-3712162-A1 SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2020-09-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175917-A1 COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR BIRC5, XIAP, BIRC2 L3MBTL1 2656/4885SSTR4 4319/4885KDM4C 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback